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ABSTRACT 
Coronary stent fractures have been suggested as a potential new mechanism of restenosis. The mechanical pro-
perties of stents were designed not only to prevent vessel recoil, but also to resist the mechanical stress of vessel 
movement over millions of cardiac cycles. We present a case in which mechanical stress may have contributed to 
the fracture of a stent implanted in a saphenous vein graft (SVG) to the left coronary artery. The patient was ad-
mitted due to chest pain 2 years after receiving a coronary artery bypass graft. A coronary angiography revealed 
the culprit vessel to be the SVG to the left coronary artery. The graft was stenosed and was stented with a siro-
limus-eluting stent. A 6-month follow-up coronary angiography revealed 80% in-stent restenosis with stent 
fracture. We re-intervened by balloon angioplasty. This is the first report of sirolimus-eluting stent fracture com-
bined with restenosis of SVG in Korea. (Korean Circ J 2009;39:251-253) 
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Introduction 
 
Drug-eluting stents have the capacity to reduce neo-
intimal hyperplasia by the local delivery of anti-proli-
ferative agents. While these stents are a very effective 
solution to the problem of restenosis, restenosis remains 
a clinical problem.
1)2) Recently, stent fracture was sug-
gested as a new potential mechanism of restenosis after 
sirolimus-eluting stent (SES) implantation.
3)4) In this 
manuscript, we describe stent fracture as a possible cause 
of restenosis. Several case reports have highlighted the 
occurrence of stent fracture at follow-up.
5) But, few case 
reports have concerned stent fracture in saphenous vein 
graft (SVG). We reported the first case of complete SES 
fracture combined with significant restenosis of a SVG 
in Korea. 
 
Case 
 
A 74-year-old woman with diabetes mellitus present-
ed with unstable angina in April 2005. She had no 
other risk factors such as hypertension, hypercholeste-
rolemia, alcohol, or smoking. She revealed a diagnosis 
of three-vessel coronary disease upon coronary angio-
graphy, and underwent coronary artery bypass graft 
surgery with placement of a SVG to the right coronary 
artery and SVG to the left anterior descending artery. 
Two years later, she was admitted with unstable an-
gina. Coronary angiography revealed 70% focal steno-
sis of the proximal SVG to the left anterior descending 
artery (Fig. 1A). The SVG to the left anterior descend-
ing artery was predilated with a 2.0×15 mm angiop-
lasty balloon at 6 atm. After predilation, a 2.75×18 
mm Cypher
® SES (Cordis, Roden, The Netherlands) 
was deployed in the SVG and inflated at 10 atm (Fig. 
1B). She tolerated the procedure well and was disch-
arged without chest pain. 
A follow-up coronary angiography was performed 
after 6 months. On admission to the hospital, the pa-
tient displayed a pulse rate of 68 beats/min, blood pres-
sure of 110/70 mmHg and respiratory rate of 18 br-
eaths/min. Her physical examination was essentially 
normal. A chest X-ray demonstrated no abnormalities 
except sutured metallic rings around the sternum. A 
complete blood count, electrolytes and thyroid func-
tion tests were within normal limits. Cardiac enzymes 
were also within normal limits. An electrocardiogram 
showed normal sinus rhythm without ST-segment ch-
ange. Transthoracic echocardiogram revealed good re- 
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gional wall motion with ejection fraction of 69%. The 
coronary angiography revealed 80% focal in-stent res-
tenosis with complete stent fracture (Fig. 2A and B). 
Intravascular ultrasound showed neointimal hyperpla-
sia at mid-stent without presence of a stent strut (Fig. 3). 
The stenosis was crossed with a guide wire and dilated 
with a 3.0×15 mm angioplasty balloon at 20 atm. A 
final coronary angiography showed thrombolysis in 
myocardial infarction (TIMI) 3 distal flow of the SVG 
without residual stenosis (Fig. 2C).  
 
Discussion 
 
In-stent restenosis after implantation of SESs still 
A  B 
Fig. 1. Angiographic views of SVG to the left anterior descending artery during the initial coronary intervention. A: angiography revealed 
70% focal stenosis of the proximal SVG to the left anterior descending artery (arrow). B: after SES implantation for the SVG, a well 
deployed stent without residual stenosis was evident (arrow). SVG: saphenous vein graft, SES: sirolimus-eluting stent. 
Fig. 2. Angiographic views of the SVG to the left anterior descending artery. A: angiography revealing 80% focal in-stent restenosis
(arrow). B: complete strut fracture of mid portion of the Cypher stent was observed (arrow). C: final angiography after balloon angio-
plasty revealing good distal flow of the SVG without residual stenosis. SVG: saphenous vein graft. 
A  B  C 
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Fig. 3. Angiographic and intravascular ultrasound images on fractured stent at SVG. A: proximal stent segment. B: point of stent fracture 
(lack of stent layer). C: distal stent segment. SVG: saphenous vein graft.  
 
Sun Hong Yoo, et al.·253 
occurs in some cases, and stent fracture was recently sug-
gested as a new potential mechanism of restenosis.
3)4) 
The “real world” clinical practice of implantation of 
SESs may be a safe and feasible technique for revas-
cularization in patients with SVG disease with excel-
lent short- and long-term clinical outcomes.
6) But, the 
use of bare-metal stents may be associated with lower 
long-term mortality than the use of SES for SVG dis-
ease.
7) An incidence of stent fracture after SES implan-
tation of 2.6% was reported.
8) While the exact mecha-
nism of stent fracture is unknown, stent fractures are 
associated with long stented segments, right coronary 
artery location and metal overlap.
9) Multiple mechani-
cal factors such as long stented segments, increased ri-
gidity and pre-procedure vessel angulation might in-
teract to disrupt the stent strut. The majority of stent 
fractures occur within 10 mm from areas of increased 
rigidity caused by strut overlap that may have acted as a 
fulcrum for metal deformation due to vessel movement. 
Dynamic vessel movement and repetitive kinking of 
the stent during the cardiac cycle may also be implicat-
ed in stent fractures.
9) Many drug-eluting stent fractures 
occur in the proximal segments of the right coronary 
artery, since this artery moves more dynamically than 
the left coronary artery during the cardiac cycle.
10) 
The implantation of multiple overlapping stents sig-
nificantly increases the axial stiffness of the stented seg-
ment and longer stents covering longer lesions are sub-
ject to higher radial forces. These may play a role in 
stent fracture.
9) SES fracture may be due to the closed 
cell design of the SES compared with the paclitaxel-el-
uting stent, which has an open cell design.
11) 
In-stent restenosis after implantation of a SES is com-
monly associated with a discontinuity in stent cover-
age.
12) Late incomplete stent strut coverage because of 
stent fracture could result in incomplete inhibition of 
intimal hyperplasia and subsequently in restenosis at 
follow-up.
10) Therefore, fractured stent struts cause a 
local mechanical irritation of the vessel and may result 
in inflammation and neointimal hyperplasia.
11) At the 
fracture point, neointimal growth is putatively observ-
ed because of the decrease in local drug delivery.
8) Fur-
thermore, exposure of a free metal strut protruding into 
the vessel lumen clearly could trigger platelet activa-
tion and resultant stent thrombosis.
11) 
In our case, a short stent was deployed in the proxi-
mal curvature portion of SVG to the left anterior de-
scending artery. Unlike the native coronary arteries, the 
body of a SVG is relatively free to move in relation to 
the anastomotic site, depending upon the degree of peri-
graft fibrosis and amount of intrathoracic space avail-
able. Consequently, in vein grafts, mechanical stresses 
can be very high.
4)13) 
As yet, there is no consensus regarding the best treat-
ment method of stent fracture. Re-stent therapy is con-
troversial, since there is a possibility of recurrence of 
stent fracture. Overlapping stents may also increase the 
likelihood of stent fractures from increased axial stiff-
ness at the overlapping segment acting as a fulcrum for 
stent deformation and fracture from vessel movement.
14) 
Furthermore, the effect of balloon angioplasty for un-
covered SES restenosis is unknown.
8) Instead of re-stent 
therapy, we treated stent fracture with balloon angio-
plasty. Follow-up studies should be performed to con-
firm that there is no in-stent restenosis. 
Stent fracture of the SVG is relatively rare. The pre-
sently-reported case is the first case of complete stent 
fracture of SVG in Korea. 
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